Jazz Pharmaceuticals plc

NASDAQ:JAZZ   3:59:50 PM EDT
176.05
+1.46 (+0.84%)
Products

Jazz Pharmaceuticals Announces FDA Approval Of Additional Indication For Vyxeos

Published: 03/30/2021 22:25 GMT
Jazz Pharmaceuticals plc (JAZZ) - Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and Cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients.